Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

Latest Prostate Cancer News and Research

Genomic test may help identify prostate cancer patients at high risk of disease progression

After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.

27 Jul 2021

New radiotracer opens the door for advancement of iron-targeted cancer therapies

A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients.

23 Jul 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

A low-cost biopolymer dressing to help heal chronic wounds

Tens of millions of patients around the world suffer from persistent and potentially life-threatening wounds. These chronic wounds, which are also a leading cause of amputation, have treatments, but the cost of existing wound dressings can prevent them from reaching people in need.

19 Jul 2021

MRI screening and targeted biopsies could reduce overdiagnoses of prostate cancer

Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.

9 Jul 2021

Research reveals recovery of cancer screening tests and associated disparities after first pandemic peak

The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell.

8 Jul 2021

Anti-androgen therapy for patients with advanced prostate cancer may fuel bone metastasis

Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.

7 Jul 2021

Artificial intelligence program analyzes CT scans for tell-tale signs of prostate cancer

Prostate cancer is the most diagnosed cancer and a leading cause of death by cancer in Australian men.

7 Jul 2021

Multimodality therapy critical for treating more aggressive prostate cancers

Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center.

1 Jul 2021

Black male veterans more likely to receive radiation or surgery for prostate cancer than non-Black men

Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows

29 Jun 2021

Study explores the potential role of gene polymorphisms in pathogenesis of prostate cancer

Oncotarget published "The presence of polymorphisms in genes controlling neurotransmitter metabolism and disease prognosis in patients with prostate cancer: a possible link with schizophrenia" reported that polymorphisms of neurotransmitter metabolism genes were studied in patients with prostate cancer (PC) characterized by either reduced or extended serum prostate-specific antigen doubling time corresponding to unfavorable and favorable disease prognosis respectively.

28 Jun 2021

Study: A subset of patients with localized prostate cancer may benefit from immunotherapies

In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called "hot" tumors with increased levels of inflammation and the presence of immune cells in and around the tumors.

24 Jun 2021

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

23 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Flinders University joins research alliance to tackle the challenges in men’s health

Flinders University has joined a ground breaking male health research alliance to create an unrivalled global entity.

21 Jun 2021

Study uncovers new mechanisms underlying lineage plasticity

Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them. While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer -- androgen receptor inhibitors such as enzalutamide, apalutamide, darolutamide, and abiraterone -- eventually these drugs stop working.

21 Jun 2021

Study: Cancer cells grown in culture dishes have less parity with their human sources

In a bid to find or refine laboratory research models for cancer that better compare with what happens in living people, Johns Hopkins Medicine scientists report they have developed a new computer-based technique showing that human cancer cells grown in culture dishes are the least genetically similar to their human sources.

18 Jun 2021

Endocrine Society praises U.S. Supreme Court's decision to uphold the ACA

The Endocrine Society today praised the U.S. Supreme Court's decision to uphold the Affordable Care Act, which makes health care accessible to millions of individuals nationwide, including those with hormone health conditions such as diabetes, osteoporosis, thyroid conditions, and breast and prostate cancer.

17 Jun 2021

Novel drug class shows potential to treat cancer patients with faulty BRCA genes

Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumors have faulty copies of the BRCA cancer genes.

17 Jun 2021

LIM domain only 1 gene contributes to the tumorigenesis of multiple cancers

Humans have been plagued by a myriad of deadly cancers since ages. Parallelly, they have also been attempting different permutations and combinations of treatments to cure the disease. Part of these attempts involving biomolecular targets have come to the fore in recent years.

10 Jun 2021